A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

• Conditions: Advanced Breast Cancer

• Registration Number: NCT03047889
• Lead Sponsor: Chinese Academy of Medical Sciences

Brief Summary

To study the epidemiological trends and characteristics for advanced breast cancer patients, to analyze these trends and report the results

Detailed Description

In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references for standardized treatment therapy, and to improve the quality of life and prolong survival time.

To study the epidemiological trends and characteristics for advanced BC patients, to analyze these trends and report the results. To learn about the current treatment therapy for advanced BC patients in different areas in China.To provide references for standardized treatment therapy, to improve the quality of patients' life and to prolong the survival time for the advanced BC patients.To assess the different treatment therapies for advanced BC with consideration of economic cost-effectiveness

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-11-29
• Status Verified: 2017-02
• Study First Submitted QC: 2017-02-07
• Last Update Submitted: 2017-02-07
• Study First Posted: 2017-02-09
• Last Update Posted: 2017-02-09
• Primary Completion: 2017-04
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 4200

Inclusion Criteria

• diagnosed as advanced breast cancer during Jan1st,2012-Dec31st,2014
• complete with surgical pathology data, auxiliary treatment, there is a clear recurrence, transfer time, place, transfer of recurrence after treatment, and curative effect evaluation details.In any age, ethnic group cases.

Exclusion Criteria

• no available medical record

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival status at 3 years	3 years	percentage of patients still alive at 3 years

Secondary Outcome Measures

Name	Time	Method
PFS	3 years	Progression-free survival of first line therapy
Survival status at 5 years	3 years	percentage of patients still alive at 5 years

Trial Locations

Locations (19)

The 307th Hospital of Military Medical Sciences; 🇨🇳 Beijing, China

Sichuan Cancer Hospital and Institute; 🇨🇳 Chengdu, China

The First Affliated Hospital of Chongqing Medical University; 🇨🇳 Chongqing, China

FuZhou General Hospital of National Miltary Command; 🇨🇳 Fuzhou, China

Sun Yat-Sen University Cancer Center; 🇨🇳 Guangzhou, China

Harbin Medical University Cancer Hospital; 🇨🇳 Harbin, China

Henan Cancer Hospital; 🇨🇳 Henan, China

Hunan Cancer Hospital; 🇨🇳 Hunan, China

Jiangsu Provinces hospital; 🇨🇳 Jiangsu, China

Tumor Hospital of Yunnan Province; 🇨🇳 Kunming, China

Scroll for more (9 remaining)